In this expert commentary, Prof. Chaur-Jong Hu of Taipei Medical University discusses practical approaches to anti-amyloid therapy in the Asia-Pacific region. Topics include early Alzheimer’s disease patient selection, amyloid biomarker confirmation, baseline and follow-up MRI, APOE genotyping, ARIA-E and ARIA-H, emergency stroke assessment, and longer-term strategies for lecanemab and donanemab.
0:00: Introduction: a new era in Alzheimer's disease treatment
1:15: From symptomatic care to disease modification: lecanemab and donanemab
4:20: Patient selection: confirming amyloid, baseline MRI, and APOE genotyping
5:48: What ARIA is and why it happens: ARIA-E, ARIA-H, and MRI sequence choice
9:20: ARIA risk factors, regional regulation, and managing ARIA in practice
12:19: Beyond amyloid clearance: maintenance, retreatment, and key takeaways